Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Supernus Pharm (NQ: SUPN )

36.16 +0.34 (+0.95%)
Streaming Delayed Price Updated: 10:23 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Supernus Pharm

< Previous 1 2 3 Next >
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million. 
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals.
In a market where value is scarce, SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
Via InvestorPlace
Recap: Supernus Pharmaceuticals Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Supernus Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Supernus Pharmaceuticals's Earnings: A Preview
Via Benzinga
NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Biotechnology And Healthcare, A Bit Of A Lull
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. 
Via Talk Markets
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. 
Via InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
Exposures Product Safety
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way. 
Via The Motley Fool
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.